TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28179226

Group type: EXPERIMENTAL
Intervention: Whole grains (WG)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Refined grains (RG)
Number of subjects: 81
Study: 25851287

Group type: EXPERIMENTAL
Intervention: Antibiotics + Vitamin E supplementation (intervention group; n=76)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Antibiotics (control group; n=76)
Number of subjects: 152
Study: 23392685

Group type: EXPERIMENTAL
Intervention: Painful heat stimuli
Number of subjects: 0

Group type: COMPARATOR
Intervention: Auditory stimuli matched for unpleasantness to heat stimuli
Number of subjects: 0
Study: 22980098

Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids (fish oil) supplementation
Number of subjects: 8
Study: 19360499

Group type: EXPERIMENTAL
Intervention: Conventional occupational therapy with modified right half-field eye-patching for 4 weeks
Number of subjects: 35

Group type: COMPARATOR
Intervention: Conventional treatment only for 4 weeks
Number of subjects: 35
Study: 17433315

Group type: EXPERIMENTAL
Intervention: Metformin 2.5 g/day
Number of subjects: 56

Group type: COMPARATOR
Intervention: Metformin 1.5 g/day
Number of subjects: 56
Study: 15206693

Group type: EXPERIMENTAL
Intervention: UVB TL01
Number of subjects: 17

Group type: COMPARATOR
Intervention: Trimethylpsoralen bath PUVA
Number of subjects: 17
Study: 11481350

Group type: EXPERIMENTAL
Intervention: Irinotecan followed by 5-FU
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Irinotecan preceded by 5-FU
Number of subjects: 33

Group type: COMPARATOR
Intervention: Both sequences at identical irinotecan doses
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Irinotecan preceding 5-FU
Number of subjects: 33
Study: 9710039

Group type: EXPERIMENTAL
Intervention: Sumatriptan
Number of subjects: 0

Group type: COMPARATOR
Intervention: Disease-matched controls
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nonteratogen controls
Number of subjects: 0
Study: 7988343

Group type: EXPERIMENTAL
Intervention: big endothelin-1 in patients with microangiopathy
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: big endothelin-1 to endothelin-1 ratio in patients with microangiopathy
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: plasma levels of endothelin-1 and big endothelin-1
Number of subjects: 33
Study: 3185647

Group type: EXPERIMENTAL
Intervention: Insulin-dependent diabetics with neuropathy
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Insulin-dependent diabetics without neuropathy
Number of subjects: 30

Group type: COMPARATOR
Intervention: Nondiabetic controls
Number of subjects: 30
Study: 30227980

Group type: EXPERIMENTAL
Intervention: Aerosolized lidocaine (10% solution, 70 mg) applied over larynx and trachea
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Cotton swabs impregnated with 1 ml of 20 mg lidocaine solution
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control group (no application)
Number of subjects: 64
Study: 31191096

Group type: EXPERIMENTAL
Intervention: Transversally compliant ergometer (TCE)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Frontal compliant ergometer (FCE)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Stable ergometer (STE)
Number of subjects: 11
Study: 28804047

Group type: EXPERIMENTAL
Intervention: High-volume resistance training (HV)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Low-volume resistance training (LV)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control (CT)
Number of subjects: 33
Study: 25169589

Group type: EXPERIMENTAL
Intervention: Paclitaxel-coated balloon (DCB) (3 µg/mm²)
Number of subjects: 131

Group type: COMPARATOR
Intervention: Paclitaxel-eluting stent (DES)
Number of subjects: 131
Study: 23274779

Group type: EXPERIMENTAL
Intervention: CMC/PEO gel treatment group
Number of subjects: 93

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 93
Study: 20953883

Group type: EXPERIMENTAL
Intervention: HMB/Glu/Arg (24 g dissolved in water twice daily for 8 weeks)
Number of subjects: 30

Group type: COMPARATOR
Intervention: No supplement (Control)
Number of subjects: 30
Study: 19894365

Group type: EXPERIMENTAL
Intervention: Liposomal methylene blue (LMB) hydrogel
Number of subjects: 13
Study: 17076319

Group type: EXPERIMENTAL
Intervention: Silica-coated composites
Number of subjects: 20

Group type: COMPARATOR
Intervention: Untreated composite resins
Number of subjects: 20

Group type: COMPARATOR
Intervention: HF-pretreated composites
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Ground surfaces of human enamel and dentin
Number of subjects: 20
Study: 14658015

Group type: EXPERIMENTAL
Intervention: perindoprilat infusion
Number of subjects: 12

Group type: COMPARATOR
Intervention: saline infusion (control)
Number of subjects: 12

Group type: COMPARATOR
Intervention: diabetic patients
Number of subjects: 12
Study: 11744411

Group type: EXPERIMENTAL
Intervention: OKT3
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Daclizumab
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: ATG
Number of subjects: 87

Group type: COMPARATOR
Intervention: Overall cohort
Number of subjects: 87
Study: 9052106

Group type: EXPERIMENTAL
Intervention: Dressings for preventing catheter exit site infections
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 8096473

Group type: EXPERIMENTAL
Intervention: 30-min oxytocin infusion regimen
Number of subjects: 245

Group type: COMPARATOR
Intervention: 15-min oxytocin infusion regimen
Number of subjects: 245
Study: 3517235

Group type: EXPERIMENTAL
Intervention: Mesulergine
Number of subjects: 31

Group type: COMPARATOR
Intervention: levodopa/benserazide (Madopar)
Number of subjects: 31
Study: 30611272

Group type: EXPERIMENTAL
Intervention: Lithuanian version of the Child Perceptions Questionnaire (CPQ11-14)
Number of subjects: 307
Study: 30396554

Group type: EXPERIMENTAL
Intervention: Weekly progesterone vaginal ring (VR)
Number of subjects: 1297

Group type: COMPARATOR
Intervention: Daily progesterone gel
Number of subjects: 1297
Study: 27379922

Group type: EXPERIMENTAL
Intervention: Tolvaptan (7.5 mg) in combination with conventional diuretics (furosemide 20 mg and spironolactone 25 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (furosemide 20 mg and spironolactone 25 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tolvaptan (7.5 mg) in combination with conventional diuretics
Number of subjects: 0
Study: 25079306

Group type: EXPERIMENTAL
Intervention: Ex‐PRESS
Number of subjects: 43

Group type: COMPARATOR
Intervention: Trabeculectomy
Number of subjects: 43
Study: 21997865

Group type: EXPERIMENTAL
Intervention: Saccharomyces boulardii (SB) 250 mg twice daily for 5 days
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 20561606

Group type: EXPERIMENTAL
Intervention: Transdiagnostic Internet‐based cognitive behavioural treatment (iCBT) program
Number of subjects: 86

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 86
Study: 16938157

Group type: EXPERIMENTAL
Intervention: Parecoxib 40 mg i.v.
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Lornoxicam 8 mg i.v.
Number of subjects: 76

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study: 16382664

Group type: EXPERIMENTAL
Intervention: 1% pyrithione zinc conditioning shampoo
Number of subjects: 40

Group type: COMPARATOR
Intervention: 2% ketoconazole shampoo
Number of subjects: 40
Study: 11953079

Group type: EXPERIMENTAL
Intervention: DNA immunoabsorbent therapy
Number of subjects: 69

Group type: COMPARATOR
Intervention: Common therapeutic group (control)
Number of subjects: 69
Study: 9606737

Group type: EXPERIMENTAL
Intervention: Acetate-free biofiltration (AFB)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Bicarbonate hemodialysis (BH)
Number of subjects: 29
Study: 7618728

Group type: EXPERIMENTAL
Intervention: Sevoflurane (9-MAC-hour)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Enflurane (9-MAC-hour)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sevoflurane and Enflurane (both 9-MAC-hour)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sevoflurane and Enflurane (prolonged anesthesia)
Number of subjects: 0
Study: 2693064

Group type: EXPERIMENTAL
Intervention: Vibratory stimulation
Number of subjects: 10

Group type: COMPARATOR
Intervention: Sound stimulus
Number of subjects: 10

Group type: COMPARATOR
Intervention: Vibratory stimulation and Sound stimulus
Number of subjects: 10
Study: 81588

Group type: EXPERIMENTAL
Intervention: Doxycycline
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Amoxicillin
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Gamma globulin immunotherapy
Number of subjects: 132

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 132
Study: 30196790

Group type: EXPERIMENTAL
Intervention: Algorithm including elevated C-reactive protein ≥30 mg/l
Number of subjects: 1088

Group type: EXPERIMENTAL
Intervention: Elevated C-reactive protein with chest and laboratory findings
Number of subjects: 1088

Group type: EXPERIMENTAL
Intervention: Modified algorithm of pyrexia or elevated C-reactive protein and chest signs with infiltrates or leukocytosis
Number of subjects: 1088

Group type: COMPARATOR
Intervention: Algorithm without elevated C-reactive protein
Number of subjects: 1088
Study: 27863211

Group type: EXPERIMENTAL
Intervention: LC‐MS/MS method
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Roche method
Number of subjects: 0
Study: 25136888

Group type: EXPERIMENTAL
Intervention: Resolute zotarolimus‐eluting stent (ZES)
Number of subjects: 1391

Group type: COMPARATOR
Intervention: XIENCE V everolimus‐eluting stent (EES)
Number of subjects: 1391
Study: 22282453

Group type: EXPERIMENTAL
Intervention: Family Intervention for Dual Disorders (FIDD)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Family Education (ED)
Number of subjects: 108
Study: 22104026

Group type: EXPERIMENTAL
Intervention: Local thermal therapy with far‐infrared rays (FIR), 20 minutes per day, twice a week, for 20 sessions
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Local thermal therapy with far‐infrared rays (FIR)
Number of subjects: 43
Study: 19276293

Group type: EXPERIMENTAL
Intervention: Wolf Motor Function Test (WMFT) with 6 tasks (hand to table [front], hand to box [front], reach and retrieve, lift can, lift pencil, and fold towel)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Constraint-Induced Movement Therapy (CIMT)
Number of subjects: 0
Study: 16687913

Group type: EXPERIMENTAL
Intervention: Larger diameter post
Number of subjects: 40

Group type: COMPARATOR
Intervention: Smaller diameter post
Number of subjects: 40
Study: 15300377

Group type: EXPERIMENTAL
Intervention: GHQ5 (General Health Questionnaire, shortened version)
Number of subjects: 450

Group type: COMPARATOR
Intervention: FACES test (visual measure of mood)
Number of subjects: 450
Study: 11406738

Group type: EXPERIMENTAL
Intervention: pegylated interferon alfa‐2b
Number of subjects: 0

Group type: COMPARATOR
Intervention: interferon alfa‐2b
Number of subjects: 0
Study: 9433596

Group type: EXPERIMENTAL
Intervention: 2 cM genetic map with alpha = 0.05
Number of subjects: 239

Group type: EXPERIMENTAL
Intervention: Follow-up of 31 plateaus from the 2 cM screen
Number of subjects: 239

Group type: EXPERIMENTAL
Intervention: Multipoint analysis
Number of subjects: 239

Group type: EXPERIMENTAL
Intervention: Replication of two-point analysis of plateau markers in replicate 80
Number of subjects: 239

Group type: EXPERIMENTAL
Intervention: Multipoint analysis in replicate 80
Number of subjects: 239

Group type: EXPERIMENTAL
Intervention: Adjustments in map density, follow-up on plateaus, and decreasing significance levels
Number of subjects: 239
Study: 8438938

Group type: EXPERIMENTAL
Intervention: Maternal blood glucose levels
Number of subjects: 158
Study: 3120758

Group type: EXPERIMENTAL
Intervention: Combination of radiotherapy (45 Gy) and chemotherapy (doxorubicin and cyclophosphamide)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Postoperative radiotherapy only
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Combination of radiotherapy and chemotherapy (cyclophosphamide, methotrexate and 5-fluorouracil)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Combination of radiotherapy and chemotherapy
Number of subjects: 86
Study: 31356802

Group type: EXPERIMENTAL
Intervention: Coronectomy
Number of subjects: 110

Group type: COMPARATOR
Intervention: Traditional extraction
Number of subjects: 110
Study: 29552783

Group type: EXPERIMENTAL
Intervention: sunitinib plus transarterial chemoembolization (SU+TACE)
Number of subjects: 104

Group type: COMPARATOR
Intervention: sorafenib plus transarterial chemoembolization (SO+TACE)
Number of subjects: 104
Study: 26992083

Group type: EXPERIMENTAL
Intervention: Adolescent-Community Reinforcement Approach (A-CRA) and assertive continuing care (ACC)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Services as usual (SAU)
Number of subjects: 126
Study: 24997747

Group type: EXPERIMENTAL
Intervention: Periarticular multimodal drug injection
Number of subjects: 70

Group type: COMPARATOR
Intervention: No injection
Number of subjects: 70
Study: 22236504

Group type: EXPERIMENTAL
Intervention: 500 mg metyrapone/20 mg oxazepam (low dose)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 1500 mg metyrapone/20 mg oxazepam (high dose)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 20332274

Group type: EXPERIMENTAL
Intervention: Vitamin D (800 IU/d)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Calcium (2.0 g/d)
Number of subjects: 92
Study: 17630547

Group type: COMPARATOR
Intervention: saquinavir/ritonavir 2000/100 mg o.d.
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: saquinavir/ketoconazole 2000/400 mg o.d.
Number of subjects: 25
Study: 15326114

Group type: EXPERIMENTAL
Intervention: Pneumatic stimuli at four temperatures
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Chemical thresholds with varying flow rates
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Mechanical thresholds with added CO2
Number of subjects: 20

Group type: COMPARATOR
Intervention: Temperature effects on chemical thresholds
Number of subjects: 20

Group type: COMPARATOR
Intervention: Temperature effects on mechanical discomfort thresholds
Number of subjects: 20
Study: 11767814

Group type: EXPERIMENTAL
Intervention: Educational program related to advance care planning
Number of subjects: 284

Group type: COMPARATOR
Intervention: Control group (no educational intervention)
Number of subjects: 284
Study: 9238166

Group type: COMPARATOR
Intervention: Standard treatment (radiotherapy)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cisplatin-containing chemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: New promising chemotherapy regimens and new fractionated radiation schedules
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Innovative therapeutic approaches (biotherapies, recombinant cytokines, antitumoral vaccine, gene therapy)
Number of subjects: 0
Study: 8424702

Group type: EXPERIMENTAL
Intervention: Selective proximal vagotomy with pyloroplasty
Number of subjects: 79

Group type: COMPARATOR
Intervention: Selective proximal vagotomy without pyloroplasty
Number of subjects: 79
Study: 3303430

Group type: EXPERIMENTAL
Intervention: Cryoanalgesia of the intercostal nerves (one minute of direct cryotherapy to at least five intercostal nerves)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control group (received standard care with methadone via lumbar epidural)
Number of subjects: 53
Study: 29685591

Group type: EXPERIMENTAL
Intervention: bococizumab 150 mg subcutaneously every 2 weeks
Number of subjects: 1578

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1578

Group type: EXPERIMENTAL
Intervention: bococizumab
Number of subjects: 1578
Study: 27514633

Group type: EXPERIMENTAL
Intervention: Surgical Plate Fixation (PF)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Intramedullary Fixation (IMF)
Number of subjects: 120
Study: 25017710

Group type: EXPERIMENTAL
Intervention: bacteriostatic normal saline (bNS)
Number of subjects: 19

Group type: COMPARATOR
Intervention: normal saline (NS)
Number of subjects: 19
Study: 22515282

Group type: EXPERIMENTAL
Intervention: restrictive oral appliance (restrict‐MMOA)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: free‐MMOA (full‐arch maxillary and mandibular oral appliances with no restrictions of mandibular movements)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: free‐MOA (conventional full‐arch flat stabilisation appliance)
Number of subjects: 11

Group type: COMPARATOR
Intervention: baseline (no oral appliance)
Number of subjects: 11
Study: 20814042

Group type: EXPERIMENTAL
Intervention: Training at lactate threshold intensity for eight weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 60
Study: 20031796

Group type: EXPERIMENTAL
Intervention: Special intervention (SI) with personalized risk factor screening, therapeutic lifestyle-change counseling, and progress reports to physicians
Number of subjects: 501

Group type: COMPARATOR
Intervention: Control intervention (CIN)
Number of subjects: 501

Group type: EXPERIMENTAL
Intervention: Special intervention (SI)
Number of subjects: 501
Study: 16643361

Group type: EXPERIMENTAL
Intervention: Triazolam administered orally 75 minutes prior to scheduled atrial shock delivery
Number of subjects: 15
Study: 14657976

Group type: EXPERIMENTAL
Intervention: Brief Psychiatric Rating Scale (BPRS 4.0)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Groningen Social Disabilities Schedule (GSDS‐II)
Number of subjects: 0
Study: 11300367

Group type: EXPERIMENTAL
Intervention: Quinaprilat (0.5 microg/dL/min)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Enalaprilat (0.5 microg/dL/min)
Number of subjects: 12
Study: 8972016

Group type: EXPERIMENTAL
Intervention: US formulation of Hemofil-M at a dose of 50 u/kg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Spanish formulation of Hemofil-M at a dose of 50 u/kg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Chromogenic assay
Number of subjects: 12

Group type: COMPARATOR
Intervention: One-stage clotting assay
Number of subjects: 12
Study: 1458938

Group type: EXPERIMENTAL
Intervention: i.v. nicardipine
Number of subjects: 139

Group type: COMPARATOR
Intervention: sodium nitroprusside
Number of subjects: 139
Study: 6141750

Group type: EXPERIMENTAL
Intervention: Alpha-blocker phenoxybenzamine (10-20 mg daily)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Combination of alpha-blocker phenoxybenzamine (10-20 mg daily) and beta-blocker sotalol (40-80 mg daily)
Number of subjects: 31
Study: 30885454

Group type: EXPERIMENTAL
Intervention: Group S (simulation training)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Group D (classroom training only)
Number of subjects: 82
Study: 29735863

Group type: EXPERIMENTAL
Intervention: Chemically-cured indirect bonding resin
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Light-cured indirect bonding resin
Number of subjects: 20

Group type: COMPARATOR
Intervention: Direct bonding control group
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: In vivo bond survival rates for both indirect resins
Number of subjects: 20
Study: 27022607

Group type: EXPERIMENTAL
Intervention: Intravenous (IV) Group: 50 mg/kg MgSO4 intravenously in 150 mL saline
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Intramuscular (IM) Group: 50 mg/kg MgSO4 in 30 mL saline injected intramuscularly
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control (C) Group: 30 mL saline injected intramuscularly
Number of subjects: 75
Study: 24311723

Group type: EXPERIMENTAL
Intervention: Dasatinib 100 mg once daily
Number of subjects: 519

Group type: COMPARATOR
Intervention: Imatinib 400 mg once daily
Number of subjects: 519
Study: 21775915

Group type: EXPERIMENTAL
Intervention: Nasogastric (NG) feeding
Number of subjects: 78

Group type: COMPARATOR
Intervention: Nasojejunal (NJ) feeding
Number of subjects: 78
Study: 20576667

Group type: EXPERIMENTAL
Intervention: Motor learning coaching
Number of subjects: 78

Group type: COMPARATOR
Intervention: Neurodevelopmental treatment
Number of subjects: 78
Study: 18186675

Group type: EXPERIMENTAL
Intervention: Fasting (F, n = 49) for 12 hours before SWL
Number of subjects: 97

Group type: COMPARATOR
Intervention: Non-fasting (NF, n = 48)
Number of subjects: 97
Study: 12895267

Group type: EXPERIMENTAL
Intervention: Interferon A (10 MU IntronA/day for 2 weeks, followed by 10 MU/2 days for 12 weeks) + ribavirin (1-1.2 g/day)
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Interferon B (5 MU/day for 14 weeks) + ribavirin (1-1.2 g/day)
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Interferon C (5 MU/2 days for 14 weeks) + ribavirin (1-1.2 g/day)
Number of subjects: 155
Study: 10907971

Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg/day
Number of subjects: 534

Group type: EXPERIMENTAL
Intervention: Fluvastatin 40 mg/day
Number of subjects: 534

Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 mg/day
Number of subjects: 534

Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg/day
Number of subjects: 534

Group type: COMPARATOR
Intervention: Other dosages of HMG-CoA reductase inhibitors
Number of subjects: 534
Study: 8969878

Group type: EXPERIMENTAL
Intervention: Active Stimulation (AS)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo Stimulation (PS)
Number of subjects: 40
Study: 1427656

Group type: EXPERIMENTAL
Intervention: Octreotide
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 6726981

Group type: EXPERIMENTAL
Intervention: Repeated doses of activated charcoal and sorbitol
Number of subjects: 10

Group type: COMPARATOR
Intervention: Single dose of charcoal and cathartic
Number of subjects: 10
Study: 31155769

Group type: EXPERIMENTAL
Intervention: Curcuma longa
Number of subjects: 136

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 136
Study: 28904371

Group type: EXPERIMENTAL
Intervention: Low dose insulin infusion
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Medium dose insulin infusion
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: High dose hydrocortisone with high insulin
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Hydrocortisone (HC)
Number of subjects: 20
Study: 26121535

Group type: EXPERIMENTAL
Intervention: Kids In Divorce Situations (KIDS) intervention
Number of subjects: 156

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 156
Study: 24158664

Group type: EXPERIMENTAL
Intervention: Automated digital wrist manometer
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Automated digital arm manometer
Number of subjects: 100

Group type: COMPARATOR
Intervention: Calibrated aneroid control device
Number of subjects: 100